Literature DB >> 11358808

Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

K Schumacher1, W Haensch, C Röefzaad, P M Schlag.   

Abstract

The purpose of this study was to explore whether there is a linkage between the infiltration of CD8(+) T cells and the risk of death from esophageal cancer. Cases of 70 consecutive patients in whom esophageal squamous cell carcinomas ( n = 33) or adenocarcinomas (n = 37) were R0-resected between 1993 and 1999 were reviewed. The presence of activated CD8(+) T cells was evaluated by quantitative real-time PCR and immunohistochemistry and compared to clinical and pathological stages. The primary end point analyzed was overall survival, and a multivariate analysis was performed to distinguish any factors conferring an improved survivorship. Intratumoral (i.t.) CD8(+) T cells accumulating within the epithelial complexes were detected in 11 of all (16%) cases: in 9 of 25 (36%) patients with Union Internationale Contrele Cancer stage I or II versus 2 of 45 (4%) patients with Union Internationale Contrele Cancer stage III or IV (P = 0.001). Intratumoral CD8(+) T cell infiltrations showed proliferative activity and also IFN-gamma secretion. The presence of i.t. CD8(+) T cell infiltration more than peritumoral infiltration was associated with a good prognosis in both squamous cell and adenocarcinomas. Multivariate analysis showed that i.t. CD8(+) T cell infiltration was an independent prognostic factor (hazard ratio, 0.5; P = 0.0004) indicating favorable outcome. In conclusion, the presence of CD8(+) T cell infiltration in esophageal carcinomas is a favorable prognostic factor that should have diagnostic and therapeutic implications.

Entities:  

Mesh:

Year:  2001        PMID: 11358808

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  179 in total

1.  Preoperative sorting of circulating T lymphocytes in patients with esophageal squamous cell carcinoma: its prognostic significance.

Authors:  Tadahiro Nozoe; Yoshihiko Maehara; Keizo Sugimachi
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

2.  BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.

Authors:  J Wang; Y Jia; S Zhao; X Zhang; X Wang; X Han; Y Wang; M Ma; J Shi; L Liu
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

3.  Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.

Authors:  Kaoru Nagato; Shinichiro Motohashi; Fumihiro Ishibashi; Kohsuke Okita; Kazuki Yamasaki; Yasumitsu Moriya; Hidehisa Hoshino; Shigetoshi Yoshida; Hideki Hanaoka; Shin-Ichiro Fujii; Masaru Taniguchi; Ichiro Yoshino; Toshinori Nakayama
Journal:  J Clin Immunol       Date:  2012-04-26       Impact factor: 8.317

4.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

Authors:  Padmanee Sharma; Yu Shen; Sijin Wen; Sachiko Yamada; Achim A Jungbluth; Sacha Gnjatic; Dean F Bajorin; Victor E Reuter; Harry Herr; Lloyd J Old; Eiichi Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

5.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

6.  Anti-angiogenesis immunotherapy.

Authors:  Jonathan D Schoenfeld; Glenn Dranoff
Journal:  Hum Vaccin       Date:  2011-09-01

7.  Cancer-immune equilibrium: questions unanswered.

Authors:  Alka Bhatia; Yashwant Kumar
Journal:  Cancer Microenviron       Date:  2011-05-24

Review 8.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.

Authors:  Jiyun Lee; Binnari Kim; Hyun Ae Jung; Yoon La Choi; Jong-Mu Sun
Journal:  Cancer Immunol Immunother       Date:  2020-10-29       Impact factor: 6.968

10.  Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer.

Authors:  Konrad Kokowski; Ulf Harnack; David C Dorn; Gabriele Pecher
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-03-31       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.